Verzenio (abemaciclib)

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

CDK4 inhibitor, CDK6 inhibitor

Related drugs:

‹

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
No biomarker	Breast Cancer	No biomarker	Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G13C	Non Small Cell Lung Cancer	KRAS G13C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B
Low NLR	Breast Cancer	Low NLR	Breast Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
High ALC	Breast Cancer	High ALC	Breast Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib + eFT226 Sensitive: B - Late Trials abemaciclib + eFT226 Sensitive : B	abemaciclib + eFT226 Sensitive: B - Late Trials abemaciclib + eFT226 Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	abemaciclib Sensitive: C1 - Off-label abemaciclib Sensitive : C1	abemaciclib Sensitive: C1 - Off-label abemaciclib Sensitive : C1
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria pembrolizumab + abemaciclib Sensitive : C2	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria pembrolizumab + abemaciclib Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	abemaciclib Sensitive: C2 – Inclusion Criteria abemaciclib Sensitive : C2	abemaciclib Sensitive: C2 – Inclusion Criteria abemaciclib Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: C2 – Inclusion Criteria abemaciclib Sensitive : C2	abemaciclib Sensitive: C2 – Inclusion Criteria abemaciclib Sensitive : C2
EGFR mutation	Lung Cancer	EGFR mutation	Lung Cancer	osimertinib + abemaciclib Sensitive: C2 – Inclusion Criteria osimertinib + abemaciclib Sensitive : C2	osimertinib + abemaciclib Sensitive: C2 – Inclusion Criteria osimertinib + abemaciclib Sensitive : C2
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
BRCA2 mutation + ER positive + PGR positive	HER2 Negative Breast Cancer	BRCA2 mutation + ER positive + PGR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
BRCA1 mutation + HER-2 negative + ER positive + PGR positive	Breast Cancer	BRCA1 mutation + HER-2 negative + ER positive + PGR positive	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus + abemaciclib Sensitive: C3 – Early Trials everolimus + abemaciclib Sensitive : C3	everolimus + abemaciclib Sensitive: C3 – Early Trials everolimus + abemaciclib Sensitive : C3
PIK3CA mutation + ER mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation + ER mutation	Hormone Receptor Positive Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib + BI-836845 Sensitive: C3 – Early Trials abemaciclib + BI-836845 Sensitive : C3	abemaciclib + BI-836845 Sensitive: C3 – Early Trials abemaciclib + BI-836845 Sensitive : C3
HER-2 mutation + CDK6 mutation	Ampulla of Vater Carcinoma	HER-2 mutation + CDK6 mutation	Ampulla of Vater Carcinoma	palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive : C3	palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab/hyaluronidase-oysk Sensitive: C3 – Early Trials palbociclib + pertuzumab + abemaciclib + ribociclib + trastuzumab / hyaluronidase-oysk Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
PD-L1 overexpression + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials pembrolizumab + abemaciclib Sensitive : C3	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials pembrolizumab + abemaciclib Sensitive : C3
CDKN2A negative	Mesothelioma	CDKN2A negative	Mesothelioma	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: C3 – Early Trials trastuzumab + abemaciclib Sensitive : C3	trastuzumab + abemaciclib Sensitive: C3 – Early Trials trastuzumab + abemaciclib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials pembrolizumab + abemaciclib Sensitive : C3	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials pembrolizumab + abemaciclib Sensitive : C3
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	abemaciclib + AZD9833 Sensitive: C3 – Early Trials abemaciclib + AZD9833 Sensitive : C3	abemaciclib + AZD9833 Sensitive: C3 – Early Trials abemaciclib + AZD9833 Sensitive : C3
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3

Verzenio (abemaciclib)

Associations
(80)

Associations
(80)

Verzenio (abemaciclib)

Associations(80)

Associations(80)

Associations
(80)

Associations
(80)